Sacroiliitis Treatment Market Overview
The global sacroiliitis treatment market was valued at USD 2,035.9 million in 2024 and is expected to grow from USD 2,164.2 million in 2025 to USD 4,000 million by 2035, registering a CAGR of 6.3% during the forecast period from 2026 to 2035. Rising prevalence of autoimmune diseases, increasing awareness of sacroiliitis, advancements in diagnostic technologies, and growing demand for biologic therapies are supporting market expansion.
North America is expected to remain the dominant regional market, valued at USD 800 million in 2024 and projected to reach USD 1.5 billion by 2035. By treatment type, medication represented a leading segment, valued at USD 865 million in 2024 and projected to reach USD 1.6 billion by 2035. The growing adoption of targeted therapies and improvements in early diagnosis are further contributing to market growth.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/sacroiliitis-treatment-market
Key Companies in the Sacroiliitis Treatment Market
Astellas Pharma
Gilead Sciences
Incyte
Horizon Therapeutics
Takeda Pharmaceutical
AbbVie
Roche
Sanofi
BristolMyers Squibb
Amgen
UCB
Pfizer
Eli Lilly
Merck
Novartis
Johnson & Johnson
The market is being driven by the increasing prevalence of inflammatory and autoimmune disorders associated with sacroiliitis. Growing patient awareness and improvements in diagnostic imaging are encouraging earlier detection and treatment. Biologics, personalized medicine, minimally invasive procedures, and advanced drug-delivery approaches are also creating opportunities for more targeted and effective disease management.
The Sacroiliitis Treatment Market is segmented by treatment type, route of administration, indication, end user, and region. Treatment types include medication, physical therapy, surgery, and lifestyle modifications. Routes of administration comprise oral, injectable, and topical treatments. Indications include acute sacroiliitis, chronic sacroiliitis, and post-traumatic sacroiliitis, while end users include hospitals, clinics, and home care settings.
Recent Developments and Market Trends:
AbbVie announced in March 2024 the acquisition of Acuita Biopharma to strengthen its autoimmune and inflammatory disease portfolio.
Takeda announced a strategic partnership with Horizon Therapeutics in June 2024 to explore next-generation therapies targeting axial spondyloarthritis and related conditions.
Eli Lilly launched a novel monoclonal antibody therapy for axial spondyloarthritis in January 2025, expanding treatment options for inflammatory conditions associated with sacroiliitis.
Biologic therapies and personalized treatment approaches are gaining traction because of their targeted mechanisms and potential to improve treatment outcomes.
Advanced diagnostic imaging technologies are improving early detection and enabling more timely intervention.
Telemedicine and digital health solutions are creating new opportunities for remote consultations, symptom monitoring, and ongoing patient management.
Reasons to Buy the Report:
Understand the current market size, growth trajectory, and forecast of the global Sacroiliitis Treatment Market through 2035.
Analyze key segments based on treatment type, route of administration, indication, end user, and region.
Evaluate regional opportunities across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
Identify major companies and understand their competitive positioning in the sacroiliitis treatment landscape.
Assess the impact of biologics, personalized medicine, advanced diagnostics, and minimally invasive treatment approaches.
Understand the major market drivers, opportunities, trends, and challenges shaping the industry.
Future Outlook:
The global Sacroiliitis Treatment Market is expected to experience steady growth through 2035 as awareness of inflammatory diseases increases and treatment options continue to advance. Rising demand for biologics, personalized therapies, improved diagnostic imaging, physical therapy, and minimally invasive interventions is expected to create sustained opportunities. Expanding healthcare access, telemedicine adoption, and continued clinical research are likely to further support innovation and market development.
➤➤Explore Our Latest Related Reports:
